Objectives: To determine if transfusing ABO compatible platelets has a greater effect on incremental change in platelet count as compared to ABO incompatible platelets in critically ill children. Design: Secondary analysis of a prospective, observational study. Transfusions were classified as either ABO compatible, major incompatibility, or minor incompatibility. The primary outcome was the incremental change in platelet count. Transfusion reactions were analyzed as a secondary outcome.
demonstrated a high mortality rate (25%) for all children receiving a platelet transfusion for any indication, as well as an independent association between total platelet dose (PLADO) and mortality (1) . In children receiving platelet transfusions, each additional dose 10 mL/kg of platelets received was associated with a 2% increase in mortality, after accounting for severity of illness represented by organ dysfunction scoring on the day of transfusion, bleeding, and the use of extracorporeal life support (ECLS). Any modifiable determinants of platelet transfusions should therefore be explored given the potential morbidity and mortality that may be associated with this therapy.
Providing ABO-identical platelet transfusions is not always considered necessary. The requirement for matching ABO blood group for platelets is not as stringent as those for RBC transfusions. Platelets express ABO blood group antigens (2) , and correspondingly the plasma found in platelet products may contain antibodies against A or B antigens, depending upon the ABO type of the donor, that may be reactive with the recipient's antigens (3) . The practice of ABO matching of platelet transfusions in blood banks is variable with no consensus guidelines; approximately 20% of hospitals have no institutional written guidelines on this topic (4) . The proportion of critically ill children receiving ABO compatible platelet transfusions has not been reported. The transfusion of ABO incompatible platelets may have the benefit of effectively increasing the availability of platelet product options, which is considered a limited resource, especially in emergencies such as life-threatening hemorrhage. Increased availability also reduces waste of platelet products, given their short storage duration (5-7 d) . However, ABO mismatching has been implicated in acute hemolysis (5) , increased fever and alloimmunization (6) , and reduced efficacy of platelet transfusions (7) .
Few studies have demonstrated the effects of ABO incompatibility in pediatric platelet transfusions (8) , and no previous studies have reported the results in critically ill children. Therefore, as the primary objective of this study, we sought to describe the efficacy of ABO compatibility on the incremental change in platelet count following platelet transfusions in critically ill pediatric patients. As a secondary objective, we evaluated associations between the receipt of ABO incompatible platelet transfusions and the occurrence of transfusion reactions.
METHODS
This study, approved by the Institutional Review Board at Weill Cornell Medicine, is an a priori secondary analysis of a prospective, observational study examining the epidemiology of platelet transfusions in critically ill children ("Point Prevalence Study of Platelet Transfusions in Critically Ill Children," otherwise known as "P 3 T") (1). Eighty-two sites from 16 countries contributed data. Each site was assigned 6 random weeks (between September 2016 and April 2017) during which they screened subjects for eligibility and enrollment. A child was enrolled if he/she was between the ages of 3 days and 16 years old and received a platelet transfusion prescribed by the intensive care medical team during one of the screening days. Patients were excluded if life expectancy was considered to be less than 24 hours, gestational age of the patient was less than 37 weeks at the time of admission, or the patient had already been enrolled in a previous screening week. In addition, they were excluded from this analysis if they received multiple pooled platelet units with different ABO compatibility or if they received several platelet transfusions in the interval between laboratory assessments. In total, 16,934 patients were screened, and 559 eligible patients receiving platelet transfusions were enrolled. Data for the P 3 T study were recorded in the Research Electronic Data Capture web data application hosted at Weill Cornell Medicine and extracted for this secondary analysis. Data regarding ABO compatibility were collected around the platelet transfusion at time of enrollment but did not include all data from every platelet transfusion received during the subject's PICU stay.
Data collected included patient demographics, reason for admission, any prior platelet transfusions during the current ICU admission, validated measures of organ dysfunction (pediatric logistic organ dysfunction [PELOD]-2 scoring) (9), information regarding the platelet product (including the ABO type of the donor and recipient), and any adverse reactions that occurred during the transfusion. The adverse reactions documented included fever of greater than or equal to 38.5°C (or increase in temperature by 1°C from baseline in a patient who was already febrile), hypotension, bronchospasm, urticaria, and hemolytic reactions. The total platelet count before and after the platelet transfusion was recorded if obtained as standard of care. The timing of the assays was determined by the medical team. The pretransfusion platelet count was assayed within 36 hours of start of the transfusion and recorded according to the following time intervals: less than 1, 1-2, 2-6, 6-12, 12-24, and 24-36 hours. The timing of the posttransfusion platelet count was recorded in relation to the completion of the transfusion of interest with the same time intervals as listed above.
ABO major incompatibility was defined as platelets from A, B, or AB donors to O recipients, or from AB donors to A or B recipients. Transfusions with bidirectional incompatibility (A donor to B recipient or B donor to A recipient) were included in the major incompatibility group. Minor incompatibility was defined as platelets from O donors to A, B, or AB recipients, or from A or B donors to AB recipients.
Demographic and clinical characteristics were described as counts and percentages or median and interquartile range (IQR) as appropriate. Categorical variables were compared using either chi-square or Fisher exact test, depending on the size of the sample. Continuous variables were compared using Kruskal-Wallis test. Two-sided p values below 0.05 were considered significant, and there was no adjustment made for multiple comparisons. If the Kruskal-Wallis test showed a statistical difference between groups, then one-to-one comparison was performed to determine which groups were significantly different. All analyses were conducted using SPSS Version 25 (IBM Corp, Armonk, NY).
incompatibility, and 28 of 503 (6%) had minor incompatibility. Seven transfusions had bidirectional incompatibility and were classified along with the major incompatibility group.
The transfusions occurred across diverse locations: 351 of 503 (70%) in North America, 81 of 503 (16%) in Europe, 35 of 503 (7%) in Oceania, 21 of 503 (4%) in Asia, and 15 of 503 (3%) in the Middle East. There was variability in the percentage of compatible transfusions given in each region: 66% in North America, 70% in Europe, 71% in Oceania, 91% in Asia, and 67% in the Middle East (p < 0.001).
The demographics and clinical characteristics are described in Table 1 . The groups were comparable across various characteristics except for median PELOD-2 scoring being slightly higher in the ABO minor incompatibility group as compared to ABO-identical transfusions or major incompatibility groups (p = 0.04). For patients weighing less than 15 kg, 161 (67%) received ABO compatible transfusions, 65 (27%) received transfusions with major incompatibility, and 15 (6%) received transfusions with minor incompatibility. The admitting diagnoses of the subjects and the therapies they received are summarized in Table 2 . There were no differences in admitting diagnoses (apart from those with septic shock and those with cardiac insufficiency not related to cardiac surgery), medications with antiplatelet effects, use of extracorporeal therapies, or median dose of platelet transfusions prior to enrollment in the study between the three groups. Patients received a median (IQR) volume of platelet transfusion (PLADO) of 30 mL/kg (13-86 mL/kg) during their PICU admission prior to enrollment in the study. The total median (IQR) number of platelet transfusions received during their entire admission was 4 (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Table 3 describes the receipt of the three ABO compatibility for bleeding versus nonbleeding indications. The indication for the platelet transfusions (treatment of bleeding vs prophylaxis) differed between the three ABO compatibility groups (p = 0.04). Thirty-two percent of the ABO compatible transfusions (110/342) were given to bleeding patients. Forty-two percent of the transfusions (56/133) with major incompatibility were given to bleeding patients and 21% of the transfusions (6/28) with minor incompatibility were given to bleeding patients. Table 4 illustrates the attributes of the platelet products transfused.
The breakdown of time intervals between the pretransfusion platelet count and the start of the transfusion of interest are as follows (data were available for 501 transfusions): 36 of 501 (7%) within less than 1 hour, 102 of 501 (20%) within 1-2 hours, 223 of 501 (44%) within 2-6 hours, 105 of 501 (21%) within 6-12 hours, 29 of 501 (6%) within 12-24 hours and six of 501 (< 2%) within 24-36 hours. The breakdown of time intervals between the end of the transfusion of interest and the posttransfusion platelet count are as follows (data on timing are available in all of the transfusions): 43 of 503 (9%) within less than 1 hour, 81 of 503 (16%) within 1-2 hours, 171 of 503 (34%) within 2-6 hours, 124 of 503 (25%) within 6-12 hours, 67 of 503 (13%) within 12-24 hours, and 17 of 503 (< 4%) within 24-36 hours. There was a wide variation in the interval changes in platelet count, corrected for a standard dose of 10 mL/kg, with the majority of interval changes occurring between -40 and +150 × 10 9 cells/L. For all transfusions, there was a median (IQR) interval rise of 28 × 10 9 cells/L (8-70 × 10 9 cells/L) for every 10 mL/kg transfused. Figure 1 shows the interval change for each ABO compatibility group. These results were consistent when bleeding and nonbleeding patients were analyzed separately. In bleeding patients, the median (IQR) interval rise was 29 × 10 9 cells/L (8-64 × 10 9 cells/L) for every 10 mL/kg transfused for ABO compatible transfusions, 23 × 10 9 cells/L (7-105 × 10 9 cells/L) (11) 18 (14) 3 (11) 0.80
Cardiac surgery no bypass 6 (2) 4 (3) 0 (0) 0.50
Cardiac-nonsurgical 27 (8) 16 (12) 6 (21) Figure 2 demonstrates the interval changes in total platelet count in bleeding versus nonbleeding subjects by ABO compatibility group. Given the possibility that the presence of extracorporeal support may bias the results since it is known to affect the incremental change in platelet count due to adherence or destruction, a subgroup analysis was performed excluding those patients on ECLS. The results were consistent. The median (IQR) interval rise was 28 × 10 Similarly, given the fact that subjects with an underlying oncologic diagnosis would have likely been exposed to more platelet transfusions and therefore have a less robust response in the incremental change in platelet count, we performed a Apheresed platelets, n (%) 288 (84) 128 (96) 27 (96) 0.001
Whole blood derived platelets, n (%) 54 (16) 5 (4) 1 (4) 0.001 Leukoreduction, n (%) 320 (94) 128 (96) 27 (100) 0.61
Irradiation, n (%) 267 (78) 111 (84) 22 (79) 0.39
Human leukocyte antigen matched, n (%) 2 (1) 0 (0) 0 (0) 0.87
Volume reduced (washed), n (%) 23 (7) 11 (8) 4 (15) 0.19
Pathogen inactivated, n (%) 16 (5) 5 (4) 2 (7) Data on transfusion reactions were available in 493 subjects. Table 5 depicts the occurrence of transfusion reactions. There was no significant difference in any transfusion reaction between the groups (p = 0.07) or in any individual adverse event. There were no hemolytic reactions or septic reactions documented during any of the transfusions.
DISCUSSION
This study reports the count increment of platelet transfusions as it relates to ABO compatibility in the largest cohort of critically ill children published to date. It is the first study to report on the proportion of ABO compatible versus incompatible platelet transfusion received and the regional variability in practice. More than two thirds of children received ABO-identical platelet transfusions. Although there were minor differences between the ABO compatibility groups regarding admitting diagnosis, the population represents a diverse cohort both in geography and pathophysiology. No patient characteristics were associated with the receipt of an ABO compatible platelet transfusion. No differences were seen in the incremental differences in platelet count following transfusion, between the compatibility groups. Likewise, no differences were seen in documented transfusion reactions, in any of the groups.
Our results should be interpreted in the context of ongoing uncertainty and controversy regarding reduced efficacy following the transfusion of ABO incompatible platelets (10, 11) . Several adult studies have reported a benefit to providing ABO compatible platelet transfusions. Increased posttransfusion platelet count increments have been reported in platelet survival studies in both healthy subjects (12) and adult hematology patients (13) (14) (15) for those who received ABO compatible as compared to platelet transfusions with major incompatibility. Randomized controlled trials have demonstrated that the differential increments in platelet count post transfusion are most pronounced in patients who have received multiple doses of platelets (generally defined as > three separate transfusions) (16) . One hypothesis relates this to the development of high titer isoagglutinins, antibodies to human leukocyte antigens, or antibodies to human platelet antigens (17) . One study of six platelet refractory patients reported that these patients who received ABO incompatible platelets have circulating immune complexes of ABO antigens and their corresponding antibodies for at least several days (18) . Circulating ABO immune complexes have been shown to affect platelet function, red cell integrity, and hemostasis in vitro (19) . Unfortunately, there was no control group in this study to determine if ABO immune complexes also occur in patients who do not have platelet refractoriness. No studies have been reported in critically ill adults.
In comparison with these studies in adults, we did not detect significant differences in posttransfusion platelet count increments when comparing ABO compatible platelet transfusions to those with major or minor compatibility in critically ill children. There are very limited published reports on the efficacy of ABO compatibility for platelet transfusions in children. One study on this topic was published by Julmy et al (8) and focused on 50 children with hematologic malignancies, solid tumors, or aplastic anemia who were receiving platelet transfusions (primarily for prophylactic indications) and who were prospectively enrolled (19) . The primary comparison was the posttransfusion platelet count (measured 1 hr after completion of the transfusion) between ABO-identical and major mismatched groups. After comparing the laboratory results of 400 transfusions, the authors reported significantly worse efficacy of ABO major mismatched transfusions as compared to matched transfusions. There was no analysis of clinical outcomes included in the study.
In comparison with the previously reported results in children, we did not detect significant differences in posttransfusion platelet count increments when comparing ABO compatible platelet transfusions to those with major or minor compatibility. Our subjects had generally been multiply transfused, and our subgroup analysis showed no differences in platelet increment after transfusion for those who had received greater than or equal to 30 mL/kg of platelet transfusions during their admission, prior to enrollment. In addition, in contrast to most other published studies, our population was quite diverse geographically and reports on regional differences. Since no accepted standard for ABO matching of platelet transfusions exists, practice varies significantly. In some European countries, the titers of antibodies to the A and B antigens are routinely measured in platelet units and then labeled as "high titer negative." (20) This allows for selection of these units specifically when incompatible platelets are transfused, thus theoretically minimizing the negative consequences. Similarly, there are regional differences in product preparation; for example, some platelet products are suspended in additive solution versus plasma (4) . These variations may also affect the incremental changes in platelet counts observed.
Despite differences seen in platelet counts following transfusion of the ABO compatible versus ABO incompatible products, many argue that there is little evidence of differences in clinical outcomes shown in adults receiving platelet transfusions (9, 10) . A recently published systematic review evaluating both randomized controlled trials and observational studies regarding ABO incompatibility of platelet transfusions concluded that the clinical benefit of ABO matching was unclear since there are inconclusive data (21) . Similarly, in a retrospective examination of the platelet transfusions administered during the PLADO study, ABO matching was not predictive of the time to bleeding, if bleeding was to occur (22) . We did not detect any differences in the rates of transfusion reactions between compatibility groups. An association between ABO compatibility and bleeding was not possible since our study did not include bleeding scores due to the lack of consensus regarding their value in children and the difficulty in obtaining these scores in an unfunded international study.
This study reports on ABO compatibility of platelet transfusions in the largest cohort of children to date. The analysis is the first to report the proportion of ABO compatible transfusions received in critically ill children. Additional strengths of our study relate to the population which represents a diverse cohort both in geography and pathophysiology. More than two thirds of children received ABO-identical platelet transfusions. No patient characteristics were associated with the receipt of an ABO compatible platelet transfusion.
However, some limitations to our study exist. Although we reported on differences in the rates of transfusion reactions between compatibility groups, we did not assess for bleeding. Due to the inherent design of a point prevalence study, compatibility data were collected around one platelet transfusion and not around every platelet transfusion received by each enrolled subject during his/her admission; it is therefore unknown whether subjects received all ABO compatible versus a combination of compatible and incompatible transfusions. Some evidence suggests that ABO incompatible transfusions can affect the incremental platelet change following subsequent transfusions (23) . As an observational study, posttransfusion platelet counts were assessed at the medical team's discretion and thus not limited to 1 hour posttransfusion assessment. We did not collect information on the variation of platelet count analyzers that was likely present between the hospitals. Additionally, each platelet transfusion contains a different number of platelets, and we did not collect information on the number of platelets in each transfused aliquot. We also did not collect information on the ABO titer status of units transfused in Europe. We did not collect information on hemolysis (apart from acute hemolytic reactions during that transfusions) which may have occurred following the transfusion. Splenomegaly, an important clinical characteristic that can affect the posttransfusion platelet counts, was not recorded.
CONCLUSIONS
In this large observational study in critically ill children, no differences were seen in incremental platelet count or transfusion reactions following the transfusion of ABO compatible platelets as compared to incompatible platelets. Because of limitations inherent to the study design, no definitive statement can be made. These results demonstrate that larger prospective studies must be performed to inform the need for ABO matching in critically ill children requiring platelet transfusions. Further confirmatory studies are needed that may require assessment of additional outcomes such as organ failure and clinical bleeding in critically ill children.
